Integral BioSystems will display in Booth 447 at 2017 AAPS Annual Exposition from November 12 to 15, 2017, at the San Diego Convention Center in San Diego, CA.

BEDFORD, MASSACHUSETTS, USA, October 26, 2017 /EINPresswire.com/ -- Boston area specialty pharmaceutical formulation CRO Integral BioSystems LLC will be in the spotlight as a participating exhibitor during the 2017 Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists from November 12-15, 2017, to be held at the San Diego Convention Center in San Diego, California.

With almost 25 years of experience in all phases of cell and tissue targeted, sustained release pharmaceutical formulation development, the firm’s CEO and President, Dr. Shikha P. Barman, will be on hand to discuss the firm’s development experience for drug delivery routes including Injectables/Infusions, Ophthalmic, Intravenous, Dermal, Rectal, Sublingual, Intranasal, Pulmonary, Otic and Buccal, with dosage forms including Creams, Suspensions, Solutions, Gels, Hydrogels, Emulsions, Microspheres, Nanocrystals and Microparticles.

With its fully-equipped, state-of-the-art 10,000 square foot facility, Integral BioSystems offers up-to-the-minute formulation development services. The USPTO has recently granted approval of one of Dr. Barman’s novel drug formulation platform technologies, OcuSurf™, appropriate for many routes and active pharmaceutical ingredients. Please stop by Booth 447 to discuss your firm’s requirements, whether you need a tried-and-true sort of product, or one that is novel with IP that is protectable.

About the Symposium
The 2017 AAPS Exposition will feature four days of over 100 scientific sessions and 2,200 posters poster presentations along with many sunrise sessions, short courses, symposia, and workshops on diverse topics.

About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development including bioanalytical, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Dave Karasic
Integral BioSystems, LLC
781-275-8059
email us here